Imaging Thymidine Uptake During Treatment for Head and Neck Cancer
头颈癌治疗期间胸苷摄取的成像
基本信息
- 批准号:7329121
- 负责人:
- 金额:$ 14.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-01 至 2009-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAftercareAmericanApplications GrantsAvidityBiopsyBloodBlood specimenBreathingCancer PatientCell CycleCell Cycle KineticsCell ProliferationCharacteristicsClinicalClinical DataClinical TrialsConditionDNADataDetectionDiagnosisDiseaseDisease-Free SurvivalEatingEnsureEvaluationExposure toGoalsHead and Neck CancerHead and neck structureIdoxuridineImageImage AnalysisIn VitroIndividualInfusion proceduresInjection of therapeutic agentInvasiveKineticsLabelLarynxMalignant NeoplasmsMalignant Squamous Cell NeoplasmMeasuresMetabolicMethodologyMethodsMorbidity - disease rateNormal tissue morphologyOperative Surgical ProceduresOutcomePatient CarePatientsPilot ProjectsPositron-Emission TomographyPredictive ValuePredictive Value of TestsPublic HealthPurposeRadiationRadiation therapyRadiolabeledRadiosurgeryRateSiteSquamous CellStagingTechniquesTestingTherapeuticThymidineThymidine KinaseTimeTissuesToxic effectTreatment EfficacyTreatment ProtocolsTreatment outcomeVenousWorkanalogbasecancer sitecancer therapycancer typechemotherapydesignhead and neck cancer patientimprovedinnovationkillingsmalignant breast neoplasmmortalityoutcome forecastpre-clinicalradiotracerresponsetongue roottooltreatment planningtumoruptake
项目摘要
DESCRIPTION (provided by applicant): Squamous cell cancer of the head and neck affects over 40,000 Americans each year. Treatment options for these cancers currently include surgery, radiation and chemotherapy either alone or in combination. These cancers and their treatment can have a profound impact on the ability to eat, speak, breathe and other important functions. Current treatment approaches are not uniformly successful, but all treatments produce significant morbidity. One key challenge to improving care for patients with this type of cancer is to use a treatment most likely to produce cure and least likely to produce toxicity for any individual patient. No test is available to determine which treatment approach is likely to help an individual patient. Treatment efficacy is currently determined months after completion of therapy. Preclinical and clinical data suggest changes in cell cycle kinetics following a brief exposure to radiotherapy, either alone or with chemotherapy, can be used to determine ultimate treatment efficacy in terms of locoregional control, disease free survival and overall survival. Determining changes in cell cycle kinetics involves infusion of potentially toxic analogs of DNA precursors and multiple biopsies, precluding routine assessment. Preclinical data also suggests that cell cycle kinetics can be inferred from the degree of avidity or uptake of radiolabeled DNA precursors. Work with one such precursor, 3'-deoxy, 3'[18F]Fluorolabeled Thymidine (FLT), suggests that rapidly dividing tissues have a higher avidity for FLT. The 18F label allows this agent to be imaged using Positron Emission Tomography (PET). The hypothesis of this proposal is that FLT uptake by the tumor before treatment, and changes in tumor uptake of FLT following a brief course of chemoradiotherapy will serve as predictors of ultimate response. This hypothesis will be examined in a clinical trial by specific aims designed to rigorously develop FLT PET imaging and optimize how imaging data is collected and analyzed. Dynamic FLT PET imaging will be obtained concurrently with serial venous and arterial blood sampling to ensure accurate FLT kinetic data. The optimal timing, correlations between blood analyses and image intensity and which imaging characteristics, such as mean or maximum intensity are most useful, will be determined. Using optimized FLT PET conditions, pretreatment and early mid treatment FLT studies will be obtained in subjects undergoing chemoradiation treatment for their head and neck cancer. Baseline FLT uptake values and the degree of change in FLT uptake will be tested for predictive value for overall survival and locoregional control in these subjects. The overall goal of this project is to develop a non-invasive, image-based tool to better individualize cancer therapy. FLT imaging may provide a means to individualize cancer treatment for patients with head and neck cancer allowing for more effective and less toxic therapy for patients with this disease. The relevance of this project to public health is significant. The purpose of this project is to develop a means of determining if cancer therapy is effective during the early stages of treatment, when alternative approaches can still be tried. The studies proposed here will refine and characterize a non-invasive imaging test that may allow treatment responses to be determined shortly after treatment has begun.
描述(由申请人提供):头颈部鳞状细胞癌每年影响超过40,000名美国人。目前,这些癌症的治疗方案包括单独或联合手术、放疗和化疗。这些癌症及其治疗会对进食、说话、呼吸和其他重要功能产生深远的影响。目前的治疗方法并不都是成功的,但所有的治疗都会产生显著的发病率。改善对这类癌症患者的护理的一个关键挑战是使用一种最有可能治愈的治疗方法,对任何一个患者来说,产生毒性的可能性最小。没有测试可以确定哪种治疗方法可能对个体患者有帮助。治疗效果目前是在治疗完成几个月后确定的。临床前和临床数据表明,无论是单独放疗还是联合化疗,短暂放疗后细胞周期动力学的变化可用于确定局部区域控制、无病生存期和总生存期方面的最终治疗效果。确定细胞周期动力学的变化包括输注DNA前体的潜在毒性类似物和多次活检,排除常规评估。临床前数据还表明,细胞周期动力学可以从放射性标记DNA前体的贪婪程度或摄取程度推断出来。对一种这样的前体,3'-脱氧,3'[18F]氟标记胸苷(FLT)的研究表明,快速分裂的组织对FLT有更高的亲和力。18F标签允许使用正电子发射断层扫描(PET)对该药物进行成像。该提议的假设是,肿瘤在治疗前对FLT的摄取,以及短暂放化疗后肿瘤对FLT摄取的变化将作为最终反应的预测因素。这一假设将在临床试验中得到检验,具体目的是严格发展FLT PET成像,优化成像数据的收集和分析方式。动态FLT PET成像将与一系列静脉和动脉血液采样同时获得,以确保准确的FLT动力学数据。将确定最佳时机、血液分析和图像强度之间的相关性以及哪种成像特征(如平均或最大强度)最有用。利用优化后的FLT PET条件,对头颈癌进行放化疗的受试者进行预处理和早期中期FLT研究。将测试基线FLT摄取值和FLT摄取的变化程度,以预测这些受试者的总体生存和局部控制。该项目的总体目标是开发一种非侵入性的、基于图像的工具,以更好地个性化癌症治疗。FLT成像可能为头颈癌患者提供个体化癌症治疗的手段,从而为该疾病患者提供更有效、毒性更小的治疗。这一项目对公共卫生具有重大意义。这个项目的目的是开发一种方法,在治疗的早期阶段确定癌症治疗是否有效,当时仍然可以尝试其他方法。这里提出的研究将改进和表征一种非侵入性成像测试,可以在治疗开始后不久确定治疗反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yusuf Menda其他文献
Yusuf Menda的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yusuf Menda', 18)}}的其他基金
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
α粒子发射肽受体靶向放射性核素治疗神经内分泌肿瘤
- 批准号:
10673599 - 财政年份:2019
- 资助金额:
$ 14.16万 - 项目类别:
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
α粒子发射肽受体靶向放射性核素治疗神经内分泌肿瘤
- 批准号:
10152579 - 财政年份:2019
- 资助金额:
$ 14.16万 - 项目类别:
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
α粒子发射肽受体靶向放射性核素治疗神经内分泌肿瘤
- 批准号:
10396517 - 财政年份:2019
- 资助金额:
$ 14.16万 - 项目类别:
Project 1: Theranostics in Neuroendocrine Tumors
项目 1:神经内分泌肿瘤的治疗诊断学
- 批准号:
10264528 - 财政年份:2015
- 资助金额:
$ 14.16万 - 项目类别:
Image-guided Diagnosis and Therapy of Neuroendocrine Tumors
神经内分泌肿瘤的影像引导诊断和治疗
- 批准号:
8687491 - 财政年份:2012
- 资助金额:
$ 14.16万 - 项目类别:
Image-guided Diagnosis and Therapy of Neuroendocrine Tumors
神经内分泌肿瘤的影像引导诊断和治疗
- 批准号:
8532860 - 财政年份:2012
- 资助金额:
$ 14.16万 - 项目类别:
Image-guided Diagnosis and Therapy of Neuroendocrine Tumors
神经内分泌肿瘤的影像引导诊断和治疗
- 批准号:
8880867 - 财政年份:2012
- 资助金额:
$ 14.16万 - 项目类别:
Image-guided Diagnosis and Therapy of Neuroendocrine Tumors
神经内分泌肿瘤的影像引导诊断和治疗
- 批准号:
8300346 - 财政年份:2012
- 资助金额:
$ 14.16万 - 项目类别:
Imaging Thymidine Uptake During Treatment for Head and Neck Cancer
头颈癌治疗期间胸苷摄取的成像
- 批准号:
7476342 - 财政年份:2007
- 资助金额:
$ 14.16万 - 项目类别:
Project 1: Theranostics in Neuroendocrine Tumors
项目 1:神经内分泌肿瘤的治疗诊断学
- 批准号:
9149653 - 财政年份:
- 资助金额:
$ 14.16万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 14.16万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 14.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10452217 - 财政年份:2022
- 资助金额:
$ 14.16万 - 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10670838 - 财政年份:2022
- 资助金额:
$ 14.16万 - 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 14.16万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 14.16万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 14.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 14.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 14.16万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 14.16万 - 项目类别: